Semaglutide Cycle Length: Treatment, Stopping & Maintenance

There is no standard on-and-off semaglutide cycle established by the trials below. For prescribed weight management, the better-supported model is ongoing treatment with regular review. That does not mean every person must continue forever. It means a calendar alone cannot decide when treatment should end.

Online, cycle may mean a few months of use followed by time off. In a study, treatment duration means how long the research plan assigned treatment. Follow-up means the period during which researchers kept checking participants, sometimes after the drug stopped. These terms are not interchangeable.

This page covers duration and stopping. The semaglutide protocol guide provides separate product and dosing background. For personal treatment, use the exact prescription label and your clinician's instructions.

The ingredient name does not tell the whole story. The U.S. labels reviewed for this guide distinguish weekly injections from daily tablets, used alongside the specified diet and activity measures. Approval for one version or patient group does not apply to every semaglutide product.

Sources: Wegovy injection and tablets label, Ozempic injection label, and Rybelsus and Ozempic tablets label. The MASH approval depends on further confirmation of clinical benefit. These are U.S. indications; local approvals can differ.

In the original Semaglutide Break discussion, the author describes six months of use with favorable results and proposes a one-month break. The post does not report completing that break and restart. It also does not identify the exact prescription product or route.

The original Cycling semaglutide thread asks about four months on and four months off before the writer has started. That is a proposed plan, not a completed experience. Replies disagree: some describe repeat use, while another describes seven months of Ozempic followed by strong hunger and weight regain over three months off. Those accounts cannot establish why the outcomes differed.

These discussions were reviewed October 15, 2026. They are a small, self-selected sample, not a survey or community consensus. We could read the original accounts, but could not verify a formulation-and-route-specific cycling regimen. In particular, a claimed reset is not a measured change in drug response. The prescription and withdrawal evidence below carries more weight.

STEP 1, STEP 4, STEP 5, and SELECT targeted a 2.4 mg weekly injection. OASIS 4 studied a 25 mg daily tablet. These identify the research formulations, not a dose recommendation. A placebo is a comparison treatment without the active drug. In a randomized study, people are assigned to groups by chance to make the comparison fairer.

Keep the study group attached to the number. For example, the STEP 4 continued-treatment group and withdrawal group had different amounts of active treatment, even though both were part of the same 68-week trial.

STEP 1 enrolled 1,961 adults with obesity, or overweight with a related health condition, without diabetes. It compared weekly semaglutide injection with placebo for 68 weeks, alongside lifestyle support. Average weight change was a 14.9% reduction with semaglutide and a 2.4% reduction with placebo.

This was a group average, not a promise for one person. The main analysis included the effects of treatment interruptions and other weight-management treatments. A result calculated only among people who stayed on the medicine can answer a different question and give a different number.

The week-68 measurement does not mean treatment only begins working then. Nor does it identify an ideal stop date. To establish a repeat cycle, a study would need to test the actual sequence of treatment, break, and restart, with clear outcomes and safety checks.

In STEP 4, 902 adults entered a 20-week lead-in, when everyone received semaglutide. Of these, 803 reached the maintenance dose and were assigned to continue treatment or switch to placebo for 48 more weeks. Both groups kept lifestyle support.

From week 20 to week 68, average weight changed by −7.9% with continued treatment versus +6.9% after the switch to placebo. These percentages start at week 20, after the lead-in weight loss. They are not changes measured from the original starting weight.

The STEP 1 extension followed 327 participants for 52 weeks after the 68-week treatment phase. Both medication and structured lifestyle support had ended.

The former semaglutide group had lost an average 17.3% before stopping. Over the next year, it regained 11.6 percentage points, about two-thirds of that loss. Average weight remained 5.6% below the original starting level. This subset's 17.3% is different from the main STEP 1 result.

Two-thirds describes the average amount regained, not how many people regained everything. This exploratory follow-up was not a new randomized stopping-versus-continuing trial. Removing lifestyle support also limits what can be attributed to drug withdrawal alone.

Discuss maintenance before stopping. This study cannot predict individual regain or establish a taper that prevents it.

The STEP 5 trial studied 304 adults for 104 weeks. Average weight change was −15.2% with semaglutide versus −2.6% with placebo. Weight loss leveled off around week 60 and was largely maintained through the rest of the trial.

That matters because a stable lower weight can be a maintained benefit. It is not, by itself, proof that the drug stopped working or that the body needs time off. STEP 5 did not compare a reset break with continued treatment.

If progress changes, review the whole picture with the prescriber: the original treatment goal, side effects, missed treatment, other medicines, food intake, and activity. A plateau alone cannot identify its cause. The decision may be to maintain, adjust, change, or stop treatment, but those choices need more information than a week count.

SELECT enrolled 17,604 adults aged 45 or older with existing cardiovascular disease and overweight or obesity, without diabetes. It tested major heart and stroke outcomes. Participants received the assigned study treatment for an average 34.2 months and were followed for an average 39.8 months. Follow-up was longer than time on treatment.

The main cardiovascular outcome occurred in 6.5% of the semaglutide group and 8.0% of the placebo group. This is a 1.5-percentage-point absolute difference; the trial reported a 20% lower risk over time, based on a hazard ratio of 0.80. That measure accounts for when events happen. It is not calculated by simply dividing those two percentages, and it is not a personal prediction.

A separate SELECT weight analysis reported weight outcomes through week 208, or four years. Mean weight change at that point was −10.2% with semaglutide and −1.5% with placebo. That adds longer-term evidence, but it does not mean every participant took uninterrupted treatment for four years.

These results should not be ranked against STEP 1 by percentage alone. SELECT enrolled an older, higher-risk population and answered a different main question. Its four-year observation also does not set either a universal four-year limit or proof of lifelong safety.

No. OASIS 4 studied daily oral semaglutide in 307 adults without diabetes. Its main weight outcomes were assessed at week 64 within a 71-week trial. Average weight change at week 64 was −13.6% with oral semaglutide and −2.2% with placebo.

This was not a trial of switching between tablets and injections, or taking regular tablet holidays. A matching ingredient does not make the formulations interchangeable. The amount absorbed and the approved instructions differ. Nor can results for one oral version be treated as a dosing plan for another.

The Rybelsus and Ozempic tablets label specifically separates those formulations. Follow the exact product's rules for missed doses and switching. A tablet is not a way to recreate an injection schedule through milligram arithmetic.

Titration means changing the dose in steps. For Wegovy injection, the initial escalation spans weeks 1–16 before the maintenance stage. That starting period is meant to help tolerability; it does not define a 16-week course followed by time off.

A maintenance dose is the dose used for ongoing treatment. Maintenance does not mean that every patient must remain on the same amount forever. It also does not mean weight can never change again. The product, indication, response, and side effects still guide review.

The trial durations on this page often include the starting phase. Counting only time at the final study dose would produce a different number. Neither count supplies a tested off-cycle period. Use the product-specific protocol background for dosing questions rather than treating the research chart as a prescription.

The studies reviewed here do not establish a standard two-, four-, or eight-week break, or show that planned breaks restore the drug's effect. They also do not establish a taper that reliably prevents regain. A clinician-led treatment change is different from a repeating cycle chosen in advance.

Stopping can happen for many reasons: side effects, pregnancy planning, another illness, access problems, or a change in goals. Those reasons need different responses. A temporary pause for a medical problem does not become evidence that healthy patients benefit from regular breaks.

If access may lapse, discuss it before the supply runs out. Ask who to contact, which health measures need review, and what the plan is if the gap lasts longer than expected. Do not replace a prescription with a research product or combine products to cover the interruption.

Half-life is the time for the drug level in the body to fall by half. The Ozempic injection label describes a half-life of about one week and drug remaining in circulation for about five weeks after the last dose.

This describes drug clearance, not a reset of appetite, body weight, or treatment response. Drug levels fall gradually; that does not prove that all effects end on one date. Multiplying the half-life cannot produce an evidence-based restart rule.

For the same reason, a pregnancy-planning interval is not a weight-loss cycling interval. The Ozempic injection label directs stopping at least two months before a planned pregnancy. Discuss this early with the treating clinician, including how the underlying condition will be managed. Other products and indications need their own review.

The FDA's guidance on unapproved GLP-1 products distinguishes approved medicines from compounded and illegally marketed versions. Compounded drugs are not FDA-approved. Semaglutide sodium and semaglutide acetate are different active ingredients from the semaglutide used in approved products.

FDA also warns about dosing errors and products sold as research materials for human use. The supplier card on this page identifies a research listing only. It does not show that the material is equivalent to the drug used in STEP, SELECT, or OASIS.

A batch analysis cannot answer every question about sterility, handling, or clinical safety. Likewise, adding cagrilintide or another compound changes the treatment being studied. Single-drug results cannot establish the benefit, duration, or safety of that combination. Read combination evidence separately rather than borrowing the longest semaglutide trial.

Common problems include nausea, vomiting, diarrhea, constipation, and abdominal discomfort. Longer studies give more time to detect harms, but a short course does not remove risk. Side effects deserve review when they happen, not only at the end of a planned course.

The Ozempic injection label warns about pancreas inflammation, gallbladder problems, dehydration-related kidney injury, and diabetic eye complications. Low blood sugar is more likely with insulin or medicines that increase insulin release. These concerns can matter even when weight is falling.

The oral semaglutide label includes a boxed warning about thyroid C-cell tumors seen in rodents; the human risk is unknown. Do not use these products with a personal or family history of medullary thyroid cancer, or MEN 2, an inherited condition that raises the risk of certain tumors. Do not use a product after a serious allergic reaction to semaglutide or one of its other ingredients.

Semaglutide slows stomach emptying. Tell the anesthesia team about it before surgery or deep sedation because stomach contents may enter the lungs, called aspiration. Do not set your own surgery-related pause. The team needs the exact medicine, recent use, symptoms, and procedure details.

A useful review starts with the reason for treatment. A weight-management goal, blood-sugar goal, kidney-risk goal, and cardiovascular-risk goal are not interchangeable. Scale weight alone cannot tell whether all of those goals have been met.

Keep a clear record of the exact product, relevant symptoms, interruptions, and agreed review date. That is more useful than tracking only how many weeks are left in a cycle. An ongoing plan should remain open to change when the person's needs change.